You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TIM3

Showing 26 - 50 of 746
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Postoperative Prevention of Tumor Trial in Shanghai (Oral NMN combined with DC cell vaccine)

Not yet recruiting
  • Postoperative Prevention of Tumor
  • Oral NMN combined with DC cell vaccine
  • Shanghai, Shanghai, China
    Shanghai Mengchao Cancer Hospital
Sep 6, 2023

MRI Assessment of Leukemia Response to Therapy

Completed
  • Acute Myelogenous Leukemia
  • 3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system
  • Portland, Oregon
    Oregon Health and Science University
Jul 27, 2019

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Worldwide (Decitabine, PDR001, MBG453)

Active, not recruiting
  • Leukemia
  • +7 more
  • Boston, Massachusetts
  • +10 more
Jan 19, 2023

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

Nasopharyngeal Carcinoma Trial in China (TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride

Recruiting
  • Nasopharyngeal Carcinoma
  • TQB2618 Injection, Pempulimab Injection, Cisplatin Injection, Gemcitabine Hydrochloride Injection
  • +2 more
  • Guangzhou, Guangdong, China
  • +3 more
Nov 28, 2022

NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)

Recruiting
  • Non-small Cell Lung Cancer
  • Hypofractionated radiotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun yat-sen university cancer center
Nov 14, 2023

Recurrent/Refractory Acute Myeloid Leukemia, MDS Trial in ChengDu (TQB2618 injection azacitidine, AZA decitabine, DAC)

Recruiting
  • Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
  • TQB2618 injection azacitidine, AZA decitabine, DAC
  • ChengDu, Sichuan, China
    West China Hospital of Sichuan University
Jun 16, 2022

Breast Cancer Trial in Istanbul (Soluble immune checkpoints)

Recruiting
  • Breast Cancer
  • Soluble immune checkpoints
  • Istanbul, Turkey
  • +1 more
Jul 14, 2022

Electrode-modiolus Distance and Cochlear Fibrosis Using Depth

Recruiting
  • Sensorineural Hearing Loss
  • Fibrosis
  • Transimedance Matrix measurements
  • +2 more
  • Montpellier, France
    University Hospital Montpellier
Jan 31, 2023

Galectin-9 in Rheumatoid Arthritis and Its Correlation With

Not yet recruiting
  • Rheumatoid Arthritis
    • (no location specified)
    Jun 21, 2022

    Immune Dysregulation in Patients With COVID-19

    Recruiting
    • COVID-19
    • Immunosuppression
    • mid covid-19 patients
    • Jinan, Shandong, China
      Qilu Hospital of Shandong University
    Jan 6, 2023

    Advanced Malignancies Trial in Worldwide (MBG453, PDR001, Decitabine)

    Terminated
    • Advanced Malignancies
    • Baltimore, Maryland
    • +13 more
    Sep 20, 2022

    Neoadjuvant Therapy in Rectal Cancer

    Recruiting
    • Rectal Cancer
    • Immune checkpoint measure
    • Istanbul, Turkey
      Istanbul Training and Research Hospital
    Jul 9, 2022

    Head and Neck Squamous Cell Carcinoma Trial in Candiolo (inulin, Pembrolizumab, Nivolumab)

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • inulin
    • +2 more
    • Candiolo, Turin, Italy
      Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
    Apr 7, 2023

    A Qualitative Investigation of CLEAT Participants

    Not yet recruiting
    • Osteoarthritis
    • Qualitative Investigation of Participant Experiences
    • (no location specified)
    Jul 6, 2023

    LY007 for r/r B-NHL and Exploration of Novel CAR-T Translational

    Not yet recruiting
    • Relapsed Non-Hodgkin Lymphoma
      • (no location specified)
      Sep 19, 2023

      Post-COVID Conditions, Obesity Trial in Baltimore, San Antonio (12-weeks of Weight Loss, 12-weeks of Weight Stability)

      Not yet recruiting
      • Post-COVID Conditions
      • Obesity
      • 12-weeks of Weight Loss
      • 12-weeks of Weight Stability
      • Baltimore, Maryland
      • +1 more
      May 25, 2023

      Study on Immune Status of Patients With COVID-19

      Recruiting
      • COVID-19
      • +2 more
      • hospitalized patient
      • Jinan, Shandong, China
        Qilu Hospital of Shandong University
      Jan 10, 2023

      Platinum-Resistant Ovarian Carcinoma Trial in Duarte (Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine)

      Recruiting
      • Platinum-Resistant Ovarian Carcinoma
      • Chimeric Antigen Receptor T-cells
      • +2 more
      • Duarte, California
        City of Hope Medical Center
      Jul 21, 2022

      Shape vs Substrate in AF

      Not yet recruiting
      • Atrial Fibrillation
      • Atrial Fibrillation, Persistent
      • Intrachamber ultrasound
      • Statistical shape analysis
      • Oxford, Oxfordshire, United Kingdom
        John Radcliffe Hospital
      Aug 7, 2023

      Long COVID Symptoms in SARS-CoV-2-positive Children in China

      Active, not recruiting
      • Symptoms and Signs
      • SBQ-LC survey
      • Beijing, China
        Capital Institute of Pediatrics
      Feb 13, 2023

      Advanced Hepatocellular Carcinoma Trial in China (Penpulimab injection, TQB2618 injection, Anlotinib Hydrochloride Capsules)

      Recruiting
      • Advanced Hepatocellular Carcinoma
      • Penpulimab injection
      • +2 more
      • Wuwei, Gansu, China
      • +7 more
      Jul 27, 2023

      Pneumococcal Infections Trial in Adelaide (Gamma-PN3, Pneumovax-23, Prevenar-13)

      Recruiting
      • Pneumococcal Infections
      • Gamma-PN3
      • +3 more
      • Adelaide, South Australia, Australia
        University of Adelaide
      Aug 1, 2023

      Melanoma Trial in BeiJing (TQB2618 injection, Terprizumab injection)

      Not yet recruiting
      • Melanoma
      • TQB2618 injection
      • Terprizumab injection
      • BeiJing, Beijing, China
        Peking University Cancer Hospital
      Jul 8, 2022

      Crosstalk Between Mucosal-Associated Invariant T Cells and Gut

      Recruiting
      • Type1diabetes
      • MAIT cells analysis
      • +4 more
      • Antony, France
      • +1 more
      Aug 2, 2022